Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
When a lung cancer patient is too symptomatic to wait for genomic testing results, the expert consensus is to initiate treatment with chemotherapy alone. Adding immunotherapy upfront is ill-advised, as its use in EGFR-mutated patients (a common finding) can be detrimental.
Related Insights
Comprehensive molecular testing (PD-L1, EGFR, ALK) is no longer reserved for advanced disease. It is now critical for all patients with stage 1B or higher resectable NSCLC *before* starting any treatment to guide neoadjuvant and adjuvant therapy decisions.
The standard of care for newly diagnosed EGFR-mutated non-small cell lung cancer has shifted from osimertinib monotherapy to combination regimens. Experts agree that combinations (e.g., osimertinib/chemo) should be the default choice, with monotherapy now reserved for cases with significant tolerability concerns.
Due to a 10-11 month overall survival benefit shown in the FLORA two regimen, leading oncologists now consider osimertinib plus chemotherapy the standard first-line treatment for metastatic EGFR-mutant NSCLC. Monotherapy is reserved only for patients who cannot tolerate or refuse chemotherapy.
Contrary to expectations from metastatic disease trials like FLAURA2, the NeoAdura study showed that combining chemotherapy with neoadjuvant osimertinib did not yield a better major pathologic response (MPR) than osimertinib alone for resectable EGFR-mutant lung cancer, questioning the role of upfront chemo in this setting.
The success of perioperative osimertinib means oncologists cannot choose the optimal strategy (targeted therapy vs. chemoimmunotherapy) for resectable lung cancer without first knowing the patient's EGFR, ALK, and PD-L1 status. This elevates biomarker profiling from a metastatic-setting tool to a critical first step in early-stage disease.
For acutely ill patients with strong clinical suspicion of SCLC, delaying treatment for biopsy confirmation can mean losing the window for effective intervention. Initiating chemotherapy in the hospital based on clinical presentation is a critical, potentially life-saving measure.
For highly symptomatic gastric cancer patients needing rapid cytoreduction, oncologists may initiate treatment with chemotherapy alone. This approach aims to quickly control the disease and avoids confounding potential drug toxicities with rapid progression before adding biomarker-driven agents.
For patients with actionable mutations like EGFR or ALK, targeted therapy is the priority, regardless of PD-L1 score. Starting immunotherapy first in these patients can significantly increase the risk of developing severe pneumonitis (ILD) when they later switch to targeted therapy like osimertinib.
The era of sequential monotherapy is over. Trials like FLORA2 (Osimertinib + chemo) show significant progression-free and overall survival benefits, making intensified upfront treatment the new standard of care for most patients, marking a major paradigm shift in treatment.
The clinical mindset for first-line EGFR-mutated lung cancer has flipped. Instead of asking who to escalate to intensified therapy, the new paradigm starts with combination treatment as the default. The focus is now on identifying specific patients (e.g., older, frail) for whom de-escalation to monotherapy is appropriate.